Intellia Therapeutics, Inc. Common Stock Earnings Dividend

Intellia Therapeutics, Inc. Common Stock’s revenue fell -9.5% since last year same period to $15.05Mn in the Q1 2026. On a quarterly growth basis, Intellia Therapeutics, Inc. Common Stock has generated -34.62% fall in its revenue since last 3-months.

Intellia Therapeutics, Inc. Common Stock’s net profit jumped 15.83% since last year same period to $-96.23Mn in the Q1 2026. On a quarterly growth basis, Intellia Therapeutics, Inc. Common Stock has generated -0.46% fall in its net profits since last 3-months.

Intellia Therapeutics, Inc. Common Stock’s net profit margin jumped 7% since last year same period to -639.49% in the Q1 2026. On a quarterly growth basis, Intellia Therapeutics, Inc. Common Stock has generated -53.67% fall in its net profit margins since last 3-months.

Intellia Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.8 - a 11.11% jump from last quarter’s estimates.

Intellia Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.8.

Intellia Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 26.36% since last year same period to -0.81 in the Q1 2026. This indicates that the Intellia Therapeutics, Inc. Common Stock has generated 26.36% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Intellia Therapeutics, Inc. Common Stock’s return on assets (ROA) stands at -0.3.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Intellia Therapeutics, Inc. Common Stock’s return on equity (ROE) stands at -0.56.